MAPT and Alzheimer disease: The findings revealed that individuals with preclinical Alzheimer’s disease, mild cognitive impairment, and Alzheimer’s disease exhibited elevated levels of core biomarkers, including Aβ1-42, P-T181-tau, P-S396-tau, and T-tau, in blood neuron-derived exosomes.